Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Gets CE Mark for HCV, HIV-1 MDx Tests

NEW YORK (GenomeWeb) – Beckman Coulter said yesterday that it has garnered CE marking for its DxN Veris HCV and DxN Veris HIV-1 assays, quantitative tests for hepatitis C virus RNA and HIV-1 RNA viral load, respectively, in human plasma.

The DxN Veris HCV assay detects HCV genotypes one to six, and is calibrated to the fourth World Health Organization International Standard for HCV. Beckman Coulter said that the assay run time is around 100 minutes, enabling faster clinical decision making and improved HCV patient management.

Meantime, the DxN Veris HIV-1 test detects HIV-1 Group M, Group N, Group O, CRF AE, and CRF AG subtypes, and is traceable to the WHO International Standard for HIV-1. It is available for 1000-µL and 175-µL sample volumes, and runs in just under 90 minutes.

The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system, a cartridge-based, fully automated, sample-to-answer instrument for quantitative molecular analysis. The platform integrates sample processing, nucleic acid extraction, reaction setup, real-time TaqMan PCR amplification, and results interpretation.

Beckman Coulter launched the DxN Veris system and first assay, a quantitative viral load test for human cytomegalovirus, in Europe in May. The Danaher-owned company also markets in Europe the DxN Veris HBV assay for quantitative measurement of hepatitis B virus in plasma and serum. The platform is not commercially available in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.